The future of T-VEC looks promising with ongoing research aimed at enhancing its efficacy and expanding its application. Combination therapies involving T-VEC and other immunotherapies, such as checkpoint inhibitors, are being actively investigated to improve treatment outcomes. Additionally, advancements in genetic engineering may lead to the development of more potent oncolytic viruses tailored for various cancer types.
